YKL-40 as neuroinflammatory biomarker for neurodegeneration: microglial activation, clinical utility in AD, PD, MS, and ALS
YKL-40 (also known as Chitinase-3-like protein 1 or CHI3L1) is a 39-kDa secreted glycoprotein belonging to the glycoside hydrolase family 18. Unlike true chitinases which have enzymatic activity, YKL-40 is a chitinase-like protein (CLP) lacking catalytic function but retaining chitin-binding properties. It is produced primarily by activated macrophages, microglia, and astrocytes in the CNS, and serves as a robust marker of neuroinflammatory responses in neurodegenerative diseases[1].
Unlike GFAP which reflects astrocyte activation, YKL-40 specifically indicates microglial activation and macrophage infiltration, providing complementary information about the innate immune component of neurodegeneration. CSF and blood YKL-40 are elevated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and other neuroinflammatory conditions, making it a versatile inflammatory biomarker[2].
YKL-40 is a member of the chitinase-like protein family with distinctive structural features[3]:
Primary structure:
Structural domains:
Key amino acid motifs:
YKL-40 production in the CNS is restricted to specific cell types[1:1]:
Microglia — Primary source in neurodegeneration:
Astrocytes — Secondary source:
Macrophages/monocytes — Peripheral contribution:
Neurons — Limited expression:
Multiple signaling pathways drive YKL-40 upregulation[1:2]:
YKL-40 elevation reflects the prominent neuroinflammatory component of neurodegenerative diseases[1:3]:
Alzheimer's Disease[2:1]:
Parkinson's Disease[4]:
Multiple Sclerosis[5]:
ALS[6]:
CSF YKL-40 elevation occurs through[3:1]:
These two astroimmune biomarkers provide complementary information[1:4]:
| Feature | YKL-40 | GFAP |
|---|---|---|
| Primary cell source | Activated microglia | Reactive astrocytes |
| Specificity | Neuroinflammation | Astrogliosis |
| AD sensitivity | Moderate | High |
| MS sensitivity | High | Moderate |
| PD sensitivity | Moderate | Low |
| ALS sensitivity | Moderate | Low |
CSF YKL-40 in AD[7]:
| Comparison | AUC | Notes |
|---|---|---|
| AD vs CN | 0.75-0.82 | Moderate accuracy |
| AD vs FTD | 0.70-0.76 | Lower than p-tau/tau biomarkers |
| MCI-AD vs stable MCI | 0.72-0.78 | Moderate predictive value |
| AD vs DLB | 0.68-0.74 | Limited discrimination |
YKL-40 provides inflammatory context to amyloid and tau biomarkers but is not suitable as a standalone diagnostic marker.
Prediction of progression[7:1]:
CSF YKL-40 in PD[8]:
| Comparison | AUC | Notes |
|---|---|---|
| PD vs CN | 0.72-0.78 | Moderate accuracy |
| PD vs PSP | 0.68-0.74 | Distinguishes some atypical parkinsonisms |
| PD vs MSA | 0.65-0.72 | Limited discrimination |
| PD dementia vs PD | 0.70-0.76 | Associates with cognitive decline |
CSF YKL-40 as MS biomarker[9]:
| Comparison | AUC | Notes |
|---|---|---|
| MS vs CN | 0.78-0.85 | Good inflammatory marker |
| MS vs other dementia | 0.70-0.78 | Limited |
| CIS to MS conversion | 0.74-0.80 | Predicts progression |
| Progressive vs relapsing | 0.76-0.82 | Higher in progressive MS |
Clinical applications in MS:
CSF YKL-40 in FTD[10]:
CSF YKL-40 in ALS[11]:
| Comparison | AUC | Notes |
|---|---|---|
| ALS vs CN | 0.75-0.82 | Moderate accuracy |
| ALS vs mimics | 0.70-0.76 | Limited |
| Fast vs slow progression | 0.68-0.74 | Higher in rapid progressors |
YKL-40 is measured using validated immunoassays[1:5]:
| Platform | Detection | Notes |
|---|---|---|
| ELISA (commercial kits) | 20-1000 pg/mL | Research standard |
| MSD | 1-1000 pg/mL | Multiplex capability |
| Simoa | 0.1-100 pg/mL | Higher sensitivity |
| Luminex | 10-10000 pg/mL | Flexibility |
CSF YKL-40 measurement:
CSF YKL-40 (platform-dependent):
| Concentration | Interpretation | Notes |
|---|---|---|
| <100 ng/mL | Normal | Cognitively unimpaired young |
| 100-150 ng/mL | Borderline | Requires clinical correlation |
| >150 ng/mL | Elevated | Indicates neuroinflammation |
Blood YKL-40:
YKL-40 is not disease-specific[1:6]:
Compared to core AD biomarkers:
| Factor | Effect | Notes |
|---|---|---|
| Age | Increases with normal aging | Age-adjusted cutoffs |
| Peripheral infection | Elevates blood YKL-40 | CNS-specific requires CSF |
| Autoimmune disease | Elevates YKL-40 | Systemic inflammation |
| Trauma | Acute elevation | Recent TBI confounds |
TSPO PET studies show YKL-40 correlates with microglial activation[12]:
YKL-40 provides insights into neuroinflammation mechanisms[13]:
In clinical trials[1:7]:
YKL-40 is a validated CSF and blood biomarker that specifically reflects microglial activation and neuroinflammation in neurodegenerative diseases. Key points:
YKL-40 provides essential information about the neuroinflammatory axis of neurodegeneration that is not captured by amyloid, tau, or axonal markers.
YKL-40 in neurodegeneration. Nature Reviews Neurology. 2022. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
YKL-40 in Alzheimer's disease. Brain. 2019. ↩︎ ↩︎
YKL-40 and microglial activation. Journal of Neuroinflammation. 2013. ↩︎ ↩︎
YKL-40 in Parkinson's disease. Movement Disorders. 2022. ↩︎
YKL-40 in multiple sclerosis. Annals of Neurology. 2010. ↩︎
YKL-40 in ALS CSF. Journal of Neurology. 2019. ↩︎
YKL-40 as biomarker for AD progression. JAMA Neurology. 2022. ↩︎ ↩︎
YKL-40 in DLB and PD. Movement Disorders. 2023. ↩︎
YKL-40 in progressive MS. Annals of Neurology. 2018. ↩︎
YKL-40 in FTD spectrum. Journal of Neurology. 2019. ↩︎
YKL-40 in ALS progression. Neurology. 2023. ↩︎
YKL-40 and neuroinflammation imaging. Neurology. 2021. ↩︎
YKL-40 in rodent models of neurodegeneration. GLIA. 2019. ↩︎